Theravance Biopharma Inc（TBPH）财务数据TBPHTheravance Biopharma Inc

Evaluating the bottom line, Theravance Biopharma, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 8.89%, while the net margin is -28.45%. These profitability ratios, combined with a Return on Equity (ROE) of 20.91%, provide a clear picture of how effectively TBPH converts its operational activities into shareholder value.

In the context of the broader market, TBPH competes directly with industry leaders such as AVTX and IMMX. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, TBPH's gross margin of 100.00% stands against AVTX's N/A and IMMX's N/A. Such benchmarking helps identify whether Theravance Biopharma, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown significant revenue growth, with Q4 2025 revenue reaching $45.89 million, but has also faced substantial net losses, including a net income loss of $5.89 million in Q2 2026. The gross margin remains strong at 100%, indicating effective cost management on sales.